These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 7232658)
21. Altered receptor sensitivity following chronic drug administration in man: the tardive dyskinesia model [proceedings]. Rubovits R Psychopharmacol Bull; 1977 Jan; 13(1):49-50. PubMed ID: 402011 [No Abstract] [Full Text] [Related]
27. Tardive dyskinesia: a clinical test of the supersensitivity hypothesis. Bowers MB; Moore D; Tarsy D Psychopharmacology (Berl); 1979 Mar; 61(2):137-41. PubMed ID: 220654 [TBL] [Abstract][Full Text] [Related]
29. GABAmimetic treatments for tardive dyskinesia: efficacy and mechanism. Tamminga CA; Thaker GK; Nguyen JA Psychopharmacol Bull; 1989; 25(1):43-6. PubMed ID: 2672071 [No Abstract] [Full Text] [Related]
30. [Neuroleptics and nicotine]. Erdmann R Psychiatr Prax; 1995 Nov; 22(6):223-7. PubMed ID: 8570751 [TBL] [Abstract][Full Text] [Related]
31. Modulation of tardive dyskinesia by estrogen: neurochemical studies in an animal model. Gordon JH; Diamond BI Trans Am Neurol Assoc; 1979; 104():97-100. PubMed ID: 553438 [No Abstract] [Full Text] [Related]
32. Symptomatic treatment of tardive dyskinesia: a word of caution. Kucharski LT; Unterwald EM Schizophr Bull; 1981; 7(4):571-3. PubMed ID: 6798690 [TBL] [Abstract][Full Text] [Related]
33. [Physiopathology and treatment of tardive dyskinesia]. Cai N; Song TS Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):252-5. PubMed ID: 3000711 [No Abstract] [Full Text] [Related]
34. GABA system: clinical research and treatment of tardive dyskinesia. Thaker GK; Hare TA; Tamminga CA Mod Probl Pharmacopsychiatry; 1983; 21():155-67. PubMed ID: 6419061 [No Abstract] [Full Text] [Related]
35. Drug-induced movement disorders. Gershanik OS Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):369-76. PubMed ID: 8099509 [TBL] [Abstract][Full Text] [Related]
36. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422 [TBL] [Abstract][Full Text] [Related]
37. Tardive dyskinesia and thioridazine. Arch Gen Psychiatry; 1984 Apr; 41(4):414-6. PubMed ID: 6703859 [No Abstract] [Full Text] [Related]
38. Social and neural determinants of aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine and gamma-aminobutyric acid systems. Miczek KA; Fish EW; De Bold JF; De Almeida RM Psychopharmacology (Berl); 2002 Oct; 163(3-4):434-58. PubMed ID: 12373445 [TBL] [Abstract][Full Text] [Related]
39. Dyskinesia. Research and treatment. Psychopharmacology Suppl; 1985; 2():1-230. PubMed ID: 3858798 [No Abstract] [Full Text] [Related]
40. Evaluation of the role of cortical GABA in the induction of abnormal involuntary movements in rats. Robin M; Palfreyman M; Zraika M; Schechter P Adv Biochem Psychopharmacol; 1981; 29():37-44. PubMed ID: 7257935 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]